← Back to Search

Risk Score

Risk Reduction Intervention for Iatrogenic Disease (AGING Trial)

N/A
Recruiting
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Baseline medication risk score of 20 or more
Hospital admission for at least 48 hours
Must not have
Discharge to hospice
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at time of intervention
Awards & highlights

Summary

This trial will test whether the MedWise Risk Score can help identify which patients are at high risk for readmission and target them for interventions.

Who is the study for?
This trial is for older adults who were in the hospital for at least 2 days, have a high medication risk score (20+), and are taking 5 or more medications upon leaving the hospital. It's not for those who left the hospital against advice, passed away during their stay, live far from the facility, or went to hospice care.
What is being tested?
The study tests if using MedWise Risk Score™ to guide treatment can lower this score and reduce chances of being readmitted within 30 days after discharge. High-risk patients will receive special attention to adjust their meds.
What are the potential side effects?
Since this intervention involves adjusting existing medications rather than testing new ones, side effects will vary based on changes made to each patient's medication regimen.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My medication risk score is 20 or higher.
Select...
I have been admitted to the hospital for at least 48 hours.
Select...
I was prescribed 5 or more medications when I left the hospital.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am being discharged to hospice care.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days after hospital discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days after hospital discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of individuals with an emergency department visit or hospital readmission
Secondary outcome measures
Difference in score between patients aged older and younger than 65 years

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Discharge medication regimen instructions will be provided upon discharge after being assessed using the MWRS, optimized, and assessed by the prescriber.
Group II: Standard of CareActive Control1 Intervention
Discharge medication regimen instructions will be provided upon discharge after being assessed by the prescriber.

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
435 Previous Clinical Trials
64,223 Total Patients Enrolled
1 Trials studying Iatrogenic Disease
80 Patients Enrolled for Iatrogenic Disease

Media Library

MedWise Risk Score™ (Risk Score) Clinical Trial Eligibility Overview. Trial Name: NCT05017948 — N/A
Iatrogenic Disease Research Study Groups: Intervention, Standard of Care
Iatrogenic Disease Clinical Trial 2023: MedWise Risk Score™ Highlights & Side Effects. Trial Name: NCT05017948 — N/A
MedWise Risk Score™ (Risk Score) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05017948 — N/A
~204 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top